NCT07750873RecruitingPhase 2
A Trial of CRD-4730 in HFrEF
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of CRD-4730 in Patients With Heart Failure With Reduced Ejection Fraction (HFrEF)
Source: ClinicalTrials.gov · Last updated 6 Aug 2026
Brief summary (registry, in English)
CRD-4730 is a calcium/calmodulin-dependent protein kinase II (CaMKII) inhibitor. The CALIBRATE-HF trial is a Phase 2, global, multi-center, randomized, double-blind, parallel-group, placebo-controlled trial. The trial will evaluate the efficacy, safety, and tolerability of CRD-4730 in addition to guideline directed medical therapy in participants with heart failure with reduced ejection fraction (HFrEF). Participants will be randomized to 1 of 4 study groups and receive investigational study drug or placebo twice daily (BID) for 24 weeks of treatment.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 525 (estimated)
- First submitted
- 17 Jul 2026
- Start date
- 15 Jul 2026
- Primary completion date
- Sept 2028
- Lead sponsor
- Cardurion Pharmaceuticals, Inc.
- Diseases
- Heart failure
- NCT number
- NCT07750873
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 525
- From 15 Jul 2026 to the primary completion date, Sept 2028
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Has acute coronary syndrome, unstable angina, persistent angina at rest, stroke, transient ischemic attack, cardiac, carotid or other major cardiovascular surgery, cardiac valve repair (surgical or nonsurgical) or surgical replacement, or carotid angioplasty within 8 weeks prior to screening or during the Screening Period.
Other illness
- Has clinical suspicion of infiltrative cardiomyopathy (eg, amyloid, sarcoid), hypertrophic cardiomyopathy (obstructive or non-obstructive), or HF secondary to severe valvular disease, active myocarditis, active pericarditis, or clinically significant congenital heart disease.
- NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Other
- Has evidence of recent HF exacerbation defined by hospitalization or requirement for IV or SQ diuretics within 4 weeks of the time of screening or during the Screening Period.
- Has a requirement for routine, scheduled outpatient IV infusions for HF (ie, inotropes, vasodilators, or diuretics) or routinely scheduled ultrafiltration.
Who the study is looking for
- Adult male or female patient ≥ 18 years of age and ≤ 85 years of age at the time of screening.
- Has a medical history supporting a diagnosis of clinical chronic heart failure (HF) syndrome with a duration of at least 8 weeks prior to the time of screening and current NYHA functional class II to III (based on investigator's assessment).
- Has left ventricular ejection fraction ≤ 40% by a centrally read transthoracic echocardiogram performed during screening.
- Has NT-proBNP level ≥ 600 pg/mL (70.8 pmol/L) at the time of screening. Patients in atrial fibrillation or flutter at the time of screening are required to have an NT-proBNP level of ≥ 900 pg/mL (106.4 pmol/L).
- Is receiving optimized and stable guideline directed HF therapy (per applicable regional or national guidelines).
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Bloomfield Hills | United States | Recruiting |
| - Coordinator of this site? Confirm its status | Pasadena | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.